Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more) Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vivos Therapeutics Inc VVOS

Healthcare Medical Devices
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically... see more

Recent & Breaking News (NDAQ:VVOS)

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire December 23, 2024

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire November 14, 2024

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

GlobeNewswire November 13, 2024

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

GlobeNewswire October 8, 2024

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire September 19, 2024

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

GlobeNewswire September 18, 2024

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire August 14, 2024

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

GlobeNewswire August 14, 2024

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

GlobeNewswire June 27, 2024

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

GlobeNewswire June 12, 2024

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote "FOR" Re-Election of Its Highly Qualified Directors

GlobeNewswire May 20, 2024

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire May 14, 2024

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

GlobeNewswire May 14, 2024

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

GlobeNewswire April 9, 2024

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

GlobeNewswire March 28, 2024

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

GlobeNewswire March 28, 2024

Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds

GlobeNewswire February 15, 2024

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

GlobeNewswire February 6, 2024

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

GlobeNewswire January 8, 2024

Vivos Therapeutics Presents Groundbreaking Event: "Empowering Women to Champion Airway"

GlobeNewswire December 11, 2023